William Alden, MD, PhD | Medical Peptide & Fatty Acid Series
Reproductive Health: GnRH Agents and Fertility Peptides
By William Alden, MD, PhD | Medical Peptide, Regenerative & Fatty Acid Series
The reproductive peptides act on the hypothalamic-pituitary-gonadal axis in two primary directions: continuous stimulation or direct antagonism that suppresses sex-hormone production for hormone-sensitive disease, and controlled stimulation that supports fertility and assisted reproduction. I work across both directions of this axis and emphasize that strategy must be matched to the therapeutic goal.
Key Agents in This Class
GnRH agonists (leuprolide, goserelin, triptorelin, histrelin, nafarelin).
Potent continuous agonists that initially cause a hormone flare followed by pituitary desensitization and profound suppression of LH/FSH and downstream sex steroids. Used for prostate cancer, endometriosis, uterine fibroids, and central precocious puberty. Available as depots, implants, and nasal spray.
GnRH antagonists (degarelix, cetrorelix, ganirelix, relugolix, elagolix, abarelix, linzagolix).
Direct receptor blockers that suppress hormones without an initial flare. Degarelix and oral relugolix are important in advanced prostate cancer; cetrorelix and ganirelix prevent premature LH surge in IVF; oral elagolix and linzagolix address endometriosis and fibroids. Most are FDA-approved; some remain regionally limited.
Gonadorelin and kisspeptin-10.
Upstream agents. Gonadorelin (native GnRH) is used diagnostically and in selected fertility protocols. Kisspeptin-10 activates KISS1R to trigger physiologic GnRH pulses and is under study for reproductive hormone regulation.
Gonadotropins (follitropin alfa/beta, urofollitropin, menotropins, choriogonadotropin alfa, lutropin alfa)
Recombinant and urinary FSH, LH, and hCG preparations that drive follicular development, ovulation triggering, and luteal support in assisted reproduction, as well as selected male hypogonadism indications. These glycoprotein hormones are properly grouped with the reproductive peptides.
Evidence and Regulatory Status
The reproductive peptides act on the hypothalamic-pituitary-gonadal axis in two primary directions: continuous stimulation or direct antagonism that suppresses sex-hormone production for hormone-sensitive disease, and controlled stimulation that supports fertility and assisted reproduction. I work across both directions of this axis and emphasize that strategy must be matched to the therapeutic goal.
Frequently Asked Questions
Why do GnRH agonists first raise hormones before lowering them?
Continuous stimulation initially recruits and activates pituitary gonadotrophs (the flare), after which receptor downregulation and desensitization produce sustained suppression. Antagonists occupy the receptor immediately and avoid the flare—preferred when an acute rise in testosterone or estrogen would be harmful.
Are fertility gonadotropins peptides?
Yes. FSH, LH, and hCG are glycoprotein peptide hormones; they are therefore included in this reproductive-peptide category.
How do oral GnRH antagonists change practice?
Agents such as relugolix and elagolix provide convenient once- or twice-daily oral dosing, faster recovery of gonadal function after discontinuation compared with long-acting depot agonists, and dose-dependent partial suppression options for endometriosis.
Clinical Perspective
Few areas of medicine illustrate two-way control of a hormonal axis as clearly as this one. Matching the pharmacologic strategy—agonist versus antagonist, continuous versus intermittent, diagnostic versus therapeutic—to the precise clinical goal remains the heart of good care.
About the Author
William “Wes” Alden, MD, PhD, is a physician-scientist and internist whose career spans academic medicine, federal clinical research, community healthcare, and medical philanthropy. His work sits at the intersection of laboratory science and bedside care, and his writing consistently returns to one theme: regenerative and metabolic therapies deserve both open-minded use and rigorous scientific and regulatory scrutiny. This series surveys the major categories of therapeutic peptides and healthful fatty acids, one blog at a time, with an emphasis on honest evidence and clear regulatory status.
Important Disclosure and Disclaimer
This content is for general education and reflects Dr. Alden’s professional perspective. It is not medical advice and does not create a doctor-patient relationship. Individual results vary, and many agents discussed are not FDA-approved for the uses described. Several peptides are not FDA-approved and have an evolving federal compounding status; products labeled for research use only are never appropriate for use in people. Most fatty acids discussed are foods or dietary supplements and are not FDA-approved to treat any condition. Any peptide or compounded agent should be used only through a licensed provider, with appropriately sourced pharmaceutical-grade material. Readers should consult a qualified healthcare professional about their own situation before pursuing any treatment.
Educational content reflecting Dr. Alden’s professional perspective. Not medical advice. Several agents named are not FDA-approved and some have an evolving compounding status. See the full disclosure accompanying this series.

October 25, 2026
4 min read




Back to Blog